KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Restructuring Costs (2017 - 2025)

Amneal Pharmaceuticals has reported Restructuring Costs over the past 9 years, most recently at $2.5 million for Q4 2025.

  • Quarterly results put Restructuring Costs at $2.5 million for Q4 2025, up 401.01% from a year ago — trailing twelve months through Dec 2025 was $4.2 million (up 78.68% YoY), and the annual figure for FY2025 was $4.2 million, up 78.68%.
  • Restructuring Costs for Q4 2025 was $2.5 million at Amneal Pharmaceuticals, up from $143000.0 in the prior quarter.
  • Over the last five years, Restructuring Costs for AMRX hit a ceiling of $7.3 million in Q4 2021 and a floor of -$612000.0 in Q4 2022.
  • Median Restructuring Costs over the past 5 years was $501500.0 (2023), compared with a mean of $950666.7.
  • Biggest five-year swings in Restructuring Costs: soared 2923.17% in 2021 and later plummeted 108.37% in 2022.
  • Amneal Pharmaceuticals' Restructuring Costs stood at $7.3 million in 2021, then tumbled by 108.37% to -$612000.0 in 2022, then skyrocketed by 118.63% to $114000.0 in 2023, then surged by 332.46% to $493000.0 in 2024, then surged by 401.01% to $2.5 million in 2025.
  • The last three reported values for Restructuring Costs were $2.5 million (Q4 2025), $143000.0 (Q3 2025), and $1.0 million (Q2 2025) per Business Quant data.